Targacept has announced that AstraZeneca will pursue the development of the company’s candidate AZD1446 as a treatment for Alzheimer’s disease.

AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor developed through a research collaboration conducted by Targacept and AstraZeneca.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Under the terms of a 2005 collaborative research and license agreement, AstraZeneca took responsibility for further development and potential commercialisation of AZD1446.

The drug will now move into a Phase II trial as an additional treatment to donepezil for patients with mild to moderate Alzheimer’s.

Targacept President and CEO J Donald deBethizy said that the planned evaluation of AZD1446 as an augmentation treatment in Alzheimer’s complements Targacept’s ongoing Phase IIb study of AZD3480 as a monotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now